Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment

PURPOSE: Esaxerenone is a novel, oral, nonsteroidal treatment for hypertension. Physiologically based pharmacokinetic (PBPK) modelling was performed to predict the drug–drug interaction (DDI) effect of cytochrome P450 (CYP)3A modulators on esaxerenone pharmacokinetics in healthy subjects and subject...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Akiko, Ishizuka, Tomoko, Yamada, Makiko, Igawa, Yoshiyuki, Shimizu, Takako, Ishizuka, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Pharmacokinetics and Disposition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724184/
https://www.ncbi.nlm.nih.gov/pubmed/34415382
http://dx.doi.org/10.1007/s00228-021-03194-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724184/
https://www.ncbi.nlm.nih.gov/pubmed/34415382
http://dx.doi.org/10.1007/s00228-021-03194-x

Ejemplares similares